Verrica Pharmaceuticals Inc
(FRA:1NE)
€
0.593
-0.0645 (-9.81%)
Market Cap: 59.47 Mil
Enterprise Value: 82.64 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 33/100 Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 12:30PM GMT
Release Date Price:
€5.5
Greg Renza
RBC Capital Markets - Analyst
-- to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, one of the senior biotechnology equity research analysts here at RBC. And we're pleased to have Verrica with us today. And joining us and representing the company is the President and CEO, Ted White.
Ted White
Verrica Pharmaceuticals Inc. - President & CEO
[Hi], it's good to be with you.
Greg Renza
RBC Capital Markets - Analyst
Ted, it's good to be with you, and a lot going on the Verrica front, especially with PDUFA coming up, a potential game changer for patients and families.
Questions & Answers
Greg Renza
RBC Capital Markets - Analyst
But maybe to just begin, Ted, and just taking a step back for those who aren't familiar or as familiar with the Verrica story, just give us a brief intro to the company and your lead asset, YCANTH.
Ted White
Verrica Pharmaceuticals Inc. - President & CEO
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot